Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 6 | 2020 | 352 | 1.260 |
Why?
|
| Curriculum | 3 | 2020 | 217 | 1.140 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2016 | 47 | 0.940 |
Why?
|
| Anti-Infective Agents | 5 | 2015 | 46 | 0.840 |
Why?
|
| Drug Utilization | 2 | 2014 | 53 | 0.810 |
Why?
|
| Bacterial Infections | 2 | 2014 | 51 | 0.800 |
Why?
|
| Education, Medical, Graduate | 3 | 2019 | 138 | 0.770 |
Why?
|
| Education, Medical, Continuing | 3 | 2020 | 58 | 0.750 |
Why?
|
| Vancomycin | 3 | 2016 | 24 | 0.740 |
Why?
|
| Teaching | 1 | 2020 | 65 | 0.600 |
Why?
|
| Communicable Diseases | 1 | 2018 | 21 | 0.560 |
Why?
|
| Drug Utilization Review | 2 | 2015 | 20 | 0.550 |
Why?
|
| Penicillanic Acid | 1 | 2016 | 6 | 0.510 |
Why?
|
| Pneumonia | 1 | 2016 | 70 | 0.490 |
Why?
|
| Organizational Policy | 1 | 2015 | 24 | 0.460 |
Why?
|
| Sepsis | 1 | 2016 | 167 | 0.450 |
Why?
|
| Students, Medical | 2 | 2013 | 136 | 0.430 |
Why?
|
| Hospitals | 2 | 2014 | 105 | 0.420 |
Why?
|
| Clinical Medicine | 1 | 2013 | 13 | 0.400 |
Why?
|
| Hospitalization | 2 | 2020 | 500 | 0.390 |
Why?
|
| Fellowships and Scholarships | 3 | 2019 | 56 | 0.390 |
Why?
|
| Health Personnel | 1 | 2014 | 131 | 0.390 |
Why?
|
| Bacteria | 1 | 2013 | 56 | 0.390 |
Why?
|
| Uncertainty | 1 | 2011 | 12 | 0.350 |
Why?
|
| Tuberculosis, Hepatic | 1 | 2010 | 2 | 0.320 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 193 | 0.310 |
Why?
|
| Physicians | 1 | 2011 | 167 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 104 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 123 | 0.290 |
Why?
|
| Humans | 18 | 2020 | 34475 | 0.290 |
Why?
|
| Communication | 2 | 2019 | 144 | 0.270 |
Why?
|
| HIV | 1 | 2007 | 26 | 0.260 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 22 | 0.260 |
Why?
|
| Internal Medicine | 2 | 2019 | 57 | 0.250 |
Why?
|
| Clostridium difficile | 2 | 2015 | 12 | 0.230 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2015 | 9 | 0.230 |
Why?
|
| Metronidazole | 2 | 2015 | 18 | 0.230 |
Why?
|
| HIV Infections | 1 | 2007 | 429 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 318 | 0.170 |
Why?
|
| Speech | 1 | 2020 | 9 | 0.160 |
Why?
|
| Documentation | 1 | 2020 | 44 | 0.150 |
Why?
|
| Personnel Selection | 1 | 2019 | 16 | 0.150 |
Why?
|
| Ethics | 1 | 2019 | 6 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 51 | 0.150 |
Why?
|
| Preceptorship | 1 | 2018 | 4 | 0.140 |
Why?
|
| Career Choice | 1 | 2019 | 45 | 0.140 |
Why?
|
| Interviews as Topic | 1 | 2019 | 272 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2018 | 81 | 0.140 |
Why?
|
| Piperacillin | 1 | 2016 | 7 | 0.130 |
Why?
|
| Acute Disease | 1 | 2016 | 276 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2016 | 207 | 0.110 |
Why?
|
| Length of Stay | 1 | 2016 | 335 | 0.110 |
Why?
|
| Middle Aged | 5 | 2020 | 12703 | 0.110 |
Why?
|
| Female | 7 | 2020 | 21491 | 0.100 |
Why?
|
| Drug Hypersensitivity | 1 | 2013 | 9 | 0.100 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2013 | 14 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2016 | 3812 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 37 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2013 | 46 | 0.100 |
Why?
|
| Aged | 4 | 2016 | 10999 | 0.100 |
Why?
|
| Bacteremia | 1 | 2013 | 69 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 59 | 0.100 |
Why?
|
| Health Policy | 1 | 2013 | 96 | 0.090 |
Why?
|
| Cost Savings | 1 | 2012 | 38 | 0.090 |
Why?
|
| Drug Costs | 1 | 2012 | 51 | 0.090 |
Why?
|
| Education, Medical | 1 | 2011 | 73 | 0.080 |
Why?
|
| Cross Infection | 1 | 2011 | 62 | 0.080 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 8 | 0.080 |
Why?
|
| Anxiety | 1 | 2011 | 206 | 0.080 |
Why?
|
| Male | 5 | 2020 | 20697 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2011 | 349 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 429 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 103 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2015 | 3618 | 0.060 |
Why?
|
| Internship and Residency | 2 | 2019 | 330 | 0.060 |
Why?
|
| United States | 3 | 2019 | 4267 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 925 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 4151 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1262 | 0.050 |
Why?
|
| North Carolina | 2 | 2020 | 1612 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2020 | 31 | 0.040 |
Why?
|
| Insurance Benefits | 1 | 2015 | 5 | 0.030 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2015 | 11 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 212 | 0.030 |
Why?
|
| Critical Illness | 1 | 2015 | 89 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 509 | 0.030 |
Why?
|
| beta-Lactams | 1 | 2013 | 7 | 0.030 |
Why?
|
| Empirical Research | 1 | 2013 | 9 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2013 | 10 | 0.030 |
Why?
|
| Tetracycline | 1 | 2013 | 14 | 0.030 |
Why?
|
| Fluoroquinolones | 1 | 2013 | 11 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2013 | 22 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 325 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 113 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 190 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 10015 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 168 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 2352 | 0.020 |
Why?
|